Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
04/2003
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030065137 Immunological methods to modulate myostatin in vertebrate subjects
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003CA2469230A1 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003CA2461709A1 Small organic molecule regulators of cell proliferation
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461305A1 Methods of suppressing microglial activation and systemic inflammatory responses
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2459943A1 Androstanes as androgen receptor modulators
04/03/2003CA2458661A1 Methods of increasing endogenous testosterone levels
04/03/2003CA2455989A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003CA2453985A1 Receptors and membrane-associated proteins
04/03/2003CA2446904A1 Delivery of drug esters through an inhalation route
04/02/2003EP1297180A2 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
04/02/2003EP1297139A2 G-protein coupled receptor org10
04/02/2003EP1297014A2 Transporters and ion channels
04/02/2003EP1296976A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
04/02/2003EP1296951A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
04/02/2003EP1296949A2 Piperidine amides as modulators of chemokine receptor activity
04/02/2003EP1296943A1 Amino acid derivatives and their use as medicines
04/02/2003EP1296940A1 Amidine derivatives as selective antagonists of nmda receptors
04/02/2003EP1296705A1 Neurotoxic oligomers
04/02/2003EP1296702A1 Neuroprotective peptides
04/02/2003EP1208100B1 Selective antagonists of a2b adenosine receptors
04/02/2003EP1114051B1 INHIBITORS OF p38
04/02/2003EP1030842B1 Metalloproteinase inhibitors
04/02/2003CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor
04/02/2003CN1407980A Heterocyclic derivatives
04/02/2003CN1407897A DHEA composition and method
04/02/2003CN1407892A Intermittent claudication remedies
04/02/2003CN1406587A Use of activated carbon in oral medicinal preparation for hyperthyroidism
04/02/2003CN1104241C Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetraphdropyridine for preparing drugs for treating amyotrophic lateral scherosis
04/01/2003US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis
04/01/2003US6541523 Methods for treating or preventing fibromyalgia using very low doses of cyclobenzaprine
03/2003
03/28/2003WO2002030871A1 Use of amino acids for treating pain
03/28/2003WO2002030869A1 5-amino-1-pentene-3-ol substituted derivatives
03/28/2003CA2424103A1 Substituted 5-amino-1-penten-3-ol derivatives
03/28/2003CA2424089A1 Use of amino acids for treating pain
03/28/2003CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025149A2 Cell populations which co-express cd49c and cd90
03/27/2003WO2003024924A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024472A2 Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
03/27/2003WO2003024453A1 Excitatory amino acid receptor antagonists
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024423A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002040506A3 Modified clostridial neurotoxins with altered biological persistence
03/27/2003WO2002022684A3 Transporters and ion channels
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059414 Cell populations which co-express CD49c and CD90
03/27/2003CA2709442A1 Cell populations which co-express cd49c and cd90
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2460184A1 Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
03/27/2003CA2460125A1 Novel compounds and compositions as cathepsin inhibitors
03/27/2003CA2459773A1 Enamel matrix protein compositions for modulating immune response
03/27/2003CA2458720A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/26/2003EP1294882A2 B7-like molecules and uses thereof
03/26/2003EP1294868A2 Adenylyl and guanylyl cyclases
03/26/2003EP1294866A2 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294729A1 2-aminoalkyl-thieno[2,3-d]pyrimidines
03/26/2003EP1294724A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
03/26/2003EP1294699A2 Modulators of tnf- alpha signalling
03/26/2003EP1294409A2 Membrane-permeant peptide complexes for medical imaging
03/26/2003EP1294391A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
03/26/2003EP1181010A4 Pharmaceutical chewing gum formulations
03/26/2003EP1173215A4 Over-coated chewing gum formulations
03/26/2003EP1124559B1 Compositions for the treatment and prevention of neurological and pathopsychological diseases
03/26/2003EP1027325B1 Lipophilic diesters of chelating agents
03/26/2003EP0998454B1 Metalloproteinase inhibitors
03/26/2003EP0606248B1 Heteroaryl amines as novel acetyl cholinesterase inhibitors
03/26/2003CN1406227A Aryl fused azapolycy clic compounds
03/26/2003CN1103762C Novel 1-ar (alk) yl-imidazolin-2-ones contg. a disubstituted amine radical in the 4th position having an anti-convulsive effect, and production method thereof
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6537969 Nutritional supplement for cerebral metabolic insufficiencies
03/25/2003US6537519 Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases
03/25/2003CA2301599C Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
03/20/2003WO2003022994A2 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
03/20/2003WO2003022877A1 Crystal structure of baff, and use thereof in drug design
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022292A1 Oral pharmaceutical formulation containing active carbon and use of the same
03/20/2003WO2003022285A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003WO2003022273A1 Methods of treating cytokine mediated diseases
03/20/2003WO2002098226B1 Method for reducing muscle fatigue through administration of adenosine triphosphate
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002069908A3 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
1 ... 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 ... 233